Inpatient and Outpatient Vyvanse Treatment Centers
- Can Vyvanse Abuse and Addiction Be Treated?
- Do I Need Addiction Treatment?
- Types of Treatment
- Dual Diagnosis Treatment
- Choose The Best Vyvanse Treatment
Vyvanse Addiction and AbuseVyvanse is a prescription stimulant - meaning it has a mechanism of action similar to drugs in the amphetamine class (also known as "amphetamine-type stimulants" or ATS). Vyvanse is used to treat attention deficit hyperactivity disorder (ADHD).
Because of its stimulant properties, Vyvanse carries a high risk for abuse and dependence.
Can Vyvanse Abuse and Addiction Be Treated?
Of course, detox is the first step in the treatment process to rid the body of all traces of Vyvanse.
Once detox has been completed, you will begin with psychosocial therapies and counseling to help with the underlying causes of your Vyvanse addiction.
Cognitive behavioral therapy (CBT) and contingency management (CM) have been shown to be effective treatment options for Vyvanse addiction, and both of these therapies can be administered in either inpatient or outpatient treatment settings.
Do I Need Addiction Treatment?
It is not always easy to identify when you have a problem with Vyvanse. Usually, the individual struggling with addiction is the last to know that there is a problem.
Fortunately, there are a few questions you can ask yourself to help determine if it is time to seek help.
- Does your Vyvanse use interfere with your work or school?
- Does Vyvanse addiction affect your relationships with friends and family?
- Are you spending an ever-increasing amount of time and resources seeking Vyvanse or using the drug?
- Have you made some bad decisions leading to violence or criminal acts while under the influence?
- Do you use Vyvanse to improve or enhance performance in school or athletics?
- Do you binge on alcohol along with the Vyvanse?
- College students and adolescents are particularly vulnerable in this category.
Types of Treatment
Dual Diagnosis Treatment
Dual diagnosis is quite prevalent within the population of individuals with Vyvanse addiction, since the drug itself is used to treat a neurological/psychological disorder (ADHD). In addition, Vyvanse addicts may also suffer from depression, anxiety, or bipolar disorder. This dual diagnosis complicates treatment slightly because of the need to control the symptoms of the underlying psychiatric illness while detoxing the user from Vyvanse.
Both clinical research in addiction and health services research have resulted in a greater integration of substance abuse treatment and treatment of co-occurring illnesses. As behavioral health care and drug addiction treatment move more into primary care settings, the capability to treat co-occurring disorders will become the expectation of these delivery systems as well.
If you received a dual diagnosis from a mental health professional before or during Vyvanse treatment, you should expect to attend some extra counseling sessions to address the mental health issues, while possibly being prescribed additional medications to treat the underlying psychological disorder.
It is important to seek treatment for your Vyvanse addiction as soon as you realize it is interfering with your daily life, whether school, work, home, family, or friends. The sooner you seek treatment for Vyvanse addiction, the less harm will be done in the long run.
Choose The Best Vyvanse Treatment
With the help and support of your family, friends, and qualified treatment specialists, you can feel confident about your choice to seek treatment.
Selecting the best Vyvanse treatment can be stressful, as there are many factors to consider. However, with the help and support of your family, friends, and qualified treatment specialists, you can feel confident about your choice to seek treatment.
Deciding what is important to you during treatment and how much money you have to spend are the first steps, as these dictate the type of treatment you should pursue (inpatient vs. outpatient, continuing to work, living at home, etc.).
You must also choose how long you want (or need) to stay in treatment, and what other amenities are important to you. A combination of these factors will help you select the treatment center that beset suits your individual needs.
Please call to speak with one of our treatment support specialists today at 1-888-993-3112Who Answers? to explore the treatment options available in your area and choose the best Vyvanse treatment that suits your individual needs.
- treatment for amphetamine-type stimulants (ATS) use disorders. Cochrane Database of Systematic Reviews, Issue 10.
- Carroll, K.M. (2011). Chapter 44: Cognitive Behavioral Therapy. In Ruiz, P., and Strain, E., eds. Substance Abuse: A Comprehensive Textbook, Fifth Edition. Philadelphia, PA: Lippincott, Williams & Wilkins, pp. 238-254.
- Fals-Stewart, W., and Lam, W.K. (2011). Family/Couples Approaches to Treatment Engagement and Therapy. In Ruiz, P., and Strain, E., eds. Previously cited.
- Higgins, S.T., and Silverman, K. (2008). Contingency Management. In Galanter, M., and Kleber, H.D., eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. Fourth Edition. Arlington, VA: American Psychiatric Publishing, Inc.
- Hill, K.P., and Weiss, R.D. (2011). Chapter 16: Amphetamines and Other Stimulants. In Ruiz, P., and Strain, E., eds. Previously cited.
- Kosten, E.R., et al., (2008). Clinical Management: Cocaine. In Galanter, M., and Kleber, H.D., eds. The American Psychiatric Publishing Textbook of Substance Abuse Treatment. Fourth Edition. Arlington, VA: American Psychiatric Publishing, Inc.
- Mee-Lee, D., et al., eds. (2013). The ASAM Criteria: Treatment Criteria for Addictive, Substance-Related, and Co-Occurring Conditions. Third Edition. Chevy Chase, MD: The Change Companies.
- Philip, N.S., et al. (2010). Pharmacologic Approaches to Treatment-Resistant Depression: A Re-examination for the Modern Era. Expert Opin Pharmacother 11(5):709-722.
- Stitzer, M., and Petry, N. (2006). Contingency Management for Treatment of Substance Abuse. Annual Review of Clinical Psychology 2:411-434.